Navigation Links
Cancer-killing compound spares healthy cells
Date:1/4/2012

This press release is available in French.

Montreal -- Lithocholic acid (LCA), naturally produced in the liver during digestion, has been seriously underestimated. A study published in the journal Oncotarget shows that LCA can kill several types of cancer cells, such as those found in some brain tumors and breast cancer.

The research team, led by Concordia University, included scientists from McGill University and the Jewish General Hospital's Lady Davis Institute in Montreal as well as the University of Saskatchewan.

Previous research from this same team showed LCA also extends the lifespan of aging yeast. This time, the team found LCA to be very selective in killing cancer cells while leaving normal cells unscathed. This could signal a huge improvement over the baby-with-the-bathwater drugs used in chemotherapy.

"LCA doesn't just kill individual cancer cells. It could also prevent the entire tumor from growing," says senior author Vladimir Titorenko, a professor in the Department of Biology and Concordia University Research Chair in Genomics, Cell Biology and Aging.

What's more, LCA prevents tumors from releasing substances that cause neighboring cancer cells to grow and proliferate. Titorenko says LCA is the only compound that targets cancer cells, which could translate into tumor-halting power.

"This is important for preventing cancer cells from spreading to other parts of the body," he says, noting that unlike other anti-aging compounds, LCA stops cancer cell growth yet lets normal cells continue to grow.

A wide effect on different types of cancers

The next step for the research team will be to test LCA's effect on different cancers in mice models. Titorenko expects that LCA will also kill cancer cells in those experiments and lead to human clinical trials. "Our study found that LCA kills not only tumors (neuroblastomas), but also human breast cancer cells," says Titorenko. "This shows that it has a wide effect on different types of cancers."

Titorenko emphasizes that unlike drugs used in chemotherapy, LCA is a natural compound that is already present in our bodies. Studies have shown that LCA can be safely administered to mice by adding it to their food. So why is LCA so deadly for cancer cells? Titorenko speculates that cancer cells have more sensors for LCA, which makes them more sensitive to the compound than normal cells.

LCA sensors send signals to mitochondria the powerhouses of all cells. It seems that when these signals are too strong, mitochondria self-destruct and bring the cell down with them. Simply put, Titorenko and his colleagues engaged in cancer cell sabotage by targeting a weakness to LCA.


'/>"/>
Contact: Nadia Kherif
Nadia.Kherif@concordia.ca
514-848-2424 x4187
Concordia University
Source:Eurekalert

Related medicine news :

1. Cancer-killing cells are caught on film in more 3-D detail than ever before
2. Compound enhances cancer-killing properties of agent in trials
3. BUSM researchers identify novel compound to halt virus replication
4. Tumor-targeting compound points the way to new personalized cancer treatments
5. New compound defeats drug-resistant bacteria
6. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
7. Scripps Research scientists identify new class of antimalarial compounds
8. Compound found in common wart treatment shows promise as leukemia therapy
9. Mushroom compound appears to improve effectiveness of cancer drugs
10. Magic Mushroom Compound Triggered Positive Personality Change in Study
11. NYU researchers develop compound to block signaling of cancer-causing protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... ... (AM)-enabled tissue fabrication, patient-matched models and surgical guides, and prosthetics and assistive ... improve patient care. Children with birth defects, soldiers with cranial injuries, conjoined ...
(Date:6/12/2019)... ... 12, 2019 , ... GlucoseZone , the first-ever clinically ... that LaurieAnn Scher, MS, RD, CDE GlucoseZone’s Chief Strategy Officer, has been ... the Year 2019, honoring best-in-class learning and development initiatives within the diabetes community. ...
(Date:6/12/2019)... ... June 12, 2019 , ... In September of 2018, NVNA and ... telehealth and remote patient monitoring. Following its full-scale launch in March, NVNA has expanded ... Since the beginning of 2019, NVNA has achieved an average all-cause hospital readmissions rate ...
(Date:6/12/2019)... ... 12, 2019 , ... The HACCP SmartStep2 Walk-Through Dual ... Sanitizers’ HACCP Footwear Sanitizing Unit equipment. The HACCP SmartStep2 adds an additional layer ... labs, and clean rooms by reducing cross-contamination from footwear before employees enter the ...
(Date:6/11/2019)... ... June 11, 2019 , ... Homecare Homebase (HCHB), the nation’s ... Cycle Management (RCM) service at the company’s annual Users Conference this week in ... HCHB Services Suite, a collection of technology-enabled services designed to alleviate the burden ...
Breaking Medicine News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... The National Comprehensive ... Chemotherapy Order Templates ( NCCN Templates ®) into the CureMD Oncology EHR to ... NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). , “The collaboration with CureMD ...
(Date:6/6/2019)... ... June 06, 2019 , ... MEDICC (Medical Education Cooperation with Cuba) has ... “This latest move is one more assault on the freedom of Americans, Cuban-Americans and ... Chair of MEDICC’s Board of Directors. , MEDICC has long stood for open ...
(Date:6/6/2019)... ... 05, 2019 , ... Cobb-Vantress, Inc. / Siloam Springs, Arkansas, ... avian influenza virus from replicating in lab-grown chicken cells, suggesting that it may ... The study was funded by Biotechnology and Biological Sciences Research Council with additional ...
Breaking Medicine Technology: